Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cymabay Therapeutics Inc.
Headquarters: Newark, CA, United States of America
Website: N/A
Year Founded: 1988
Status: Acquired
BioCentury | Jan 23, 2025
Management Tracks
New COOs for Vividion, Edgewise
Plus: Pacira names new heads of commercial, CBO and updates from Vib spinout Tanai, Arcus, Kyverna and Alx
BioCentury | Sep 5, 2024
Data Byte
FDA’s new drug approvals in August include a Dupixent competitor, a targeted glioma therapy, and more
Agency approved seven new therapies in August, plus four new product formulations or dosages
BioCentury | Aug 3, 2024
Data Byte
Seven more PDUFA dates in August
After starting the month with two approvals, FDA’s remaining decisions include Gilead’s seladelpar, Regeneron’s BCMAxCD3 bispecific
BioCentury | Jul 31, 2024
Data Byte
I&I buying spree continues
2024 has already brought half a dozen M&A deals over $1B targeting immunology and inflammation
BioCentury | Jul 17, 2024
Data Byte
FDA’s five NME approvals in June bring 1H24 total to 21
Ipsen’s Iqirvo, Geron’s Rytelo among June highlights
BioCentury | Apr 19, 2024
Management Tracks
Domain, Initial among quartet of biotechs unveiling CEOs
Plus: Jim Jenson becomes CEO of Morphoceuticals, and updates from Xeno, NeoGenomics, DeepUll and Verastem
BioCentury | Apr 12, 2024
Deals
In $4.9B Alpine deal, Vertex sees best-in-class therapy with room for label expansions
Buyer believes povetacicept can outshine others in BAFF/APRIL class, even if not first to market — and can become a pipeline-in-a-product
BioCentury | Mar 27, 2024
Management Tracks
Rocket names Mirati vet Ondrey CFO
Plus: Syed Rizvi joins Poseida as CMO, and updates from Tvardi, Echosens and Bicara
BioCentury | Feb 13, 2024
Deals
Deal report: Gilead buys CymaBay, BioNTech taps Autolus’ CAR T manufacturing, and more
BioCentury’s weekly roundup of biopharma deals
BioCentury | Feb 13, 2024
Product Development
ADCs, psychedelics & biotech IPOs: BioCentury’s latest podcast
Plus: Gilead’s $4.3B takeout of CymaBay
Items per page:
1 - 10 of 83